|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8134 USD | +6.40% |
|
+10.43% | -60.13% |
| Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
| Apr. 02 | Top Midday Decliners | MT |
Gritstone bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 16.34 million compared to USD 19.95 million a year ago. Net loss was USD 138.49 million compared to USD 119.69 million a year ago.
Basic loss per share from continuing operations was USD 1.2 compared to USD 1.32 a year ago. Diluted loss per share from continuing operations was USD 1.2 compared to USD 1.32 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -60.13% | 86.54M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
GRITSTONE BIO, INC. 
